Last reviewed · How we verify
Dexmedetomidine sedation
Dexmedetomidine sedation is a Alpha-2 adrenergic agonist Small molecule drug developed by KK Women's and Children's Hospital. It is currently in Phase 3 development for Sedation in pediatric patients undergoing procedural sedation, ICU sedation in mechanically ventilated patients. Also known as: Dex.
Dexmedetomidine is a selective alpha-2 adrenergic agonist that produces sedation and analgesia by activating alpha-2 receptors in the central nervous system.
Dexmedetomidine is a selective alpha-2 adrenergic agonist that produces sedation and analgesia by activating alpha-2 receptors in the central nervous system. Used for Sedation in pediatric patients undergoing procedural sedation, ICU sedation in mechanically ventilated patients.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Dexmedetomidine sedation |
|---|---|
| Also known as | Dex |
| Sponsor | KK Women's and Children's Hospital |
| Drug class | Alpha-2 adrenergic agonist |
| Target | Alpha-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesia and Sedation |
| Phase | Phase 3 |
Mechanism of action
Dexmedetomidine binds to alpha-2 adrenergic receptors in the locus coeruleus and other brain regions, reducing norepinephrine release and producing dose-dependent sedation, analgesia, and anxiolysis. Unlike other sedatives, it maintains airway reflexes and allows patients to be aroused, making it suitable for procedural and ICU sedation. The drug also has sympathomimetic effects at higher doses due to peripheral alpha-2 receptor activation.
Approved indications
- Sedation in pediatric patients undergoing procedural sedation
- ICU sedation in mechanically ventilated patients
Common side effects
- Hypotension
- Bradycardia
- Hypertension (transient, initial)
- Dry mouth
- Rebound hypertension on withdrawal
Key clinical trials
- Awareness Neuraxial Versus General Anesthesia in Frail Patients Undergoing Laparoscopic or Robotic Abdominopelvic Surgery. (NA)
- Safety and Efficacy of Dexmedetomidate vs. Midazolam for Procedural Sedation During Medical Thoracoscopy (PHASE3)
- Characteristic Electroencephalogram of General Anesthesia
- Study of the Efficacy of Moderate Sedation With Intra-NAsal Dexmedetomidine Monitored by EEG MOnitoring (NA)
- Comparison of Anesthetic Techniques for Early Recovery After Ankle Arthroscopy (NA)
- The Use of Remimazolam Versus Dexmedetomidine for Patients Receiving Drug-Induced Sleep Endoscopy (NA)
- Dexmedetomidine Use in Infants Undergoing Cooling Due to Neonatal Encephalopathy (DICE Trial) (PHASE2)
- An Exploratory Study of the Efficacy and Safety of Esketamine and Dexmedetomidine in Non-Intubated ICU Patients With Hyperactive Delirium (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexmedetomidine sedation CI brief — competitive landscape report
- Dexmedetomidine sedation updates RSS · CI watch RSS
- KK Women's and Children's Hospital portfolio CI
Frequently asked questions about Dexmedetomidine sedation
What is Dexmedetomidine sedation?
How does Dexmedetomidine sedation work?
What is Dexmedetomidine sedation used for?
Who makes Dexmedetomidine sedation?
Is Dexmedetomidine sedation also known as anything else?
What drug class is Dexmedetomidine sedation in?
What development phase is Dexmedetomidine sedation in?
What are the side effects of Dexmedetomidine sedation?
What does Dexmedetomidine sedation target?
Related
- Drug class: All Alpha-2 adrenergic agonist drugs
- Target: All drugs targeting Alpha-2 adrenergic receptor
- Manufacturer: KK Women's and Children's Hospital — full pipeline
- Therapeutic area: All drugs in Anesthesia and Sedation
- Indication: Drugs for Sedation in pediatric patients undergoing procedural sedation
- Indication: Drugs for ICU sedation in mechanically ventilated patients
- Also known as: Dex
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing